# Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

> **NCT04835168** · PHASE1 · WITHDRAWN · sponsor: **NImmune Biopharma**

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** BT-11 low
- **DRUG:** BT-11 high
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04835168
- **Lead sponsor:** NImmune Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-30
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The closure of the study is driven by the decision to redesign the study protocol for future studies.
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835168, "Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04835168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*